The reduced VLDL secretion observed in individuals with MASH appears to be due to impaired synthesis rates of VLDL particles and a reduction in apoB100 and MTTP (a protein essential for integrating TAG into VLDL particles [201]) mRNA expression levels [32]. The gene discussed is MTTP; the disease is metabolic dysfunction-associated steatohepatitis.